** Shares of drug developer Xilio Therapeutics XLO.O more than double to $1.37 premarket
** AbbVie ABBV.N and XLO enters into collaboration and option agreement to develop cancer immunotherapies
** Under terms of the deal, XLO to receive $52 million in an upfront payment and will be eligible to receive up to about $2.1 billion in milestone payments
** Deal gives ABBV access to XLO's proprietary tumor-activation technology to develop new immunotherapies
** In the last 12 months, XLO has fallen 7%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.